Ibipinabant

Ibipinabant (SLV319) is a potent, selective and orally active antagonist of cannabinoid CB1 receptor, with a Ki of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (Ki=7943 nM) . Ibipinabant can be used for the research of obesity and diabetic[1][2][3].

Product Specifications

CAS Number

[464213-10-3]

Product Name Alternative

SLV319; BMS-646256

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Cannabinoid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ibipinabant.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

C/N=C(N1N=C(C2=CC=C(Cl)C=C2)[C@@H](C3=CC=CC=C3)C1)\NS(=O)(C4=CC=C(Cl)C=C4)=O

Molecular Formula

C23H20Cl2N4O2S

Molecular Weight

487.40

Precautions

H315, H319, H335

References & Citations

[1]Lange JHM, et, al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB (1) cannabinoid receptor antagonists. J Med Chem. 2004 Jan 29;47 (3) :627-43.|[2]Tam J, et, al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 2012 Aug 8;16 (2) :167-79.|[3]Rohrbach K, et, al. Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight. Diabetes Obes Metab. 2012 Jun;14 (6) :555-64.